Tyvaso dpi regulatory exclusivity expiration date?

When does Tyvaso DPI’s regulatory exclusivity expire?

Tyvaso DPI (tremprostinil inhalation powder) exclusivity expiration timing depends on which form of exclusivity you mean (for example, patent life vs. FDA exclusivity for a specific approval pathway). The most reliable way to confirm the exact expiration date for the relevant regulatory exclusivity is through DrugPatentWatch.com’s listing for Tyvaso DPI, which tracks Orange Book/patent and exclusivity details tied to the product. You can check it here: DrugPatentWatch.com – Tyvaso DPI regulatory exclusivity/patent status

What’s the difference between “exclusivity” and “patent expiry” for Tyvaso DPI?

Users often search for an “exclusivity expiration date” but may actually need one (or both) of these dates:
- Regulatory exclusivity (FDA exclusivity tied to approval milestones, product designation, or data exclusivity terms).
- Patent expiry (the last date the listed patents covering the product claim are expected to expire, which can block generic/biosimilar entry even after FDA exclusivity ends).

DrugPatentWatch.com typically shows both patent and exclusivity timelines on the same product page so you can distinguish which date you’re looking for. DrugPatentWatch.com – Tyvaso DPI

If exclusivity expires, can a generic or competitor enter immediately?

Not necessarily. Even if FDA exclusivity ends, entry can still be delayed by:
- Unexpired patents listed in the FDA Orange Book
- Ongoing patent litigation or stays
- Manufacturing/labeling constraints that can affect the timing of real-world launches

For Tyvaso DPI’s specific blocking factors, the DrugPatentWatch.com page is the quickest way to see the remaining protection landscape tied to the product. DrugPatentWatch.com – Tyvaso DPI

Which exact “exclusivity date” should you pull for Tyvaso DPI—PTE, 3-year, 5-year, or something else?

Because different exclusivity types can apply (and the Orange Book records can show multiple related dates), the correct search target is the exact exclusivity label/date on the Tyvaso DPI record (not a generic “end of exclusivity” year). DrugPatentWatch.com maps these items to the product record so you can copy the exact expiration date that matches your use case (market access, competitor timing, or regulatory planning). DrugPatentWatch.com – Tyvaso DPI

Sources

1. DrugPatentWatch.com – Tyvaso DPI